NASDAQ NMS - GLOBAL MARKET · AMLX
+0.00% · +$0.0000 · Vol Not reported
Market closed · last close shown
Amylyx Pharmaceuticals Inc

Amylyx Pharmaceuticals Inc

Pharmaceuticals
$18.27
+ Add to watchlist
Card

Veridion Score

Refresh
Score snapshot refresh in progress
Veridion Score History · 90D

Composite trend over time

HISTORY REFRESH IN PROGRESS
REFRESHES DAILY
AI Analysis
Sovereign

Why is AMLX moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Amylyx Pharmaceuticals Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2022
Employees
136
Country
US

Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$18.27
Last session
Day high
$18.27
Last session
Day low
$18.27
Last session
Previous close
$18.27
52W high
$18.70
-2.30% from high
52W low
$13.41
92% of range
Market cap
$2B
EPS
$-1.6200
Shares out
111.2M
VWAP
$18.27
Last session
Price history computed in-house
1W
+2.70%
SMA 50 $16.37 · above
SMA 200 $16.37 · above
52W position 92%
Veridion warehouse edge

Warehouse intelligence for AMLX.

Veridion Score
76
0: 501: 522: 673: 704: 835: Not reported
Congress 30d
0
No recent disclosure on file.
Insider activity
See Form 4 panel below.
13F holders
None on file
Capital Web snapshots checked.
Disclosure-sourced lobbying and contract detail remains attributed in the full panels below.
Data ledger
Quote and day range
Refresh interval: 30 seconds
Source: Market data
Veridion Score
Coverage building
Source: Veridion methodology
Chart and risk context
Daily bars with no missing-bar fill
Source: Market data
News and filings
Refresh intervals shown inside each panel
Source: Market news and federal filings
Financials
Statements refresh in progress
SEC Form 4 ledger

AMLX insider activity

Amylyx Pharmaceuticals Inc

Score
Coverage building
Pressure
Net selling
Filings
33
Buys / sells
6 / 27
Net value
-$4.2M
Insiders
6
Named filers
FK
Firestone Karen
Insider
Leadership
KB
Klee Justin B.
Insider
Leadership
CB
Cohen Joshua B
Insider
Leadership
Cluster

No multi-insider buying cluster in the last 90 days

Net pressure

Net selling: -$4.2M across loaded Form 4 rows.

Convergence not established

Loaded official disclosures do not show all three sources aligned on this ticker.

Filing dateTrade dateInsiderTitleTypePriceQtyOwnedValueReceipt
2026-05-262026-05-21Firestone KarenInsiderbuy$13.513,80066,900$51KSEC Form 4
2026-03-042026-03-02Klee Justin B.Insidersell$14.4729,2823,334,616$424KSEC Form 4
2026-03-042026-03-02Cohen Joshua BInsidersell$14.4829,2823,334,683$424KSEC Form 4
2026-03-042026-03-02Mazzariello GinaInsidersell$14.526,844134,430$99KSEC Form 4
2026-03-042026-03-02Bedrosian Camille LInsidersell$14.586,461169,295$94KSEC Form 4
Full Form 4 history requires Sovereign

Showing 5 recent rows. Sovereign unlocks 28 additional rows, full sorting, and the named-filer history.

Upgrade to Sovereign · $25/mo
Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology
Congress · 90D
Congress filing snapshot refresh in progress
Federal contracts

AMLX contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for AMLX in this window.
Lobbying spend

AMLX lobbying filings, year to date.

Registered lobbying filings matched to Amylyx Pharmaceuticals Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for AMLX in this window.
Latest news · AMLX
Refresh interval: 5 minutes · Source: Market news insights
News snapshot refresh in progress
Analyst ratings
Sovereign unlock shows live analyst consensus for AMLX.
Options
Sovereign unlock shows live options positioning for AMLX.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.